Tongfang Kontafarma Holdings Limited (1312.HK)
HKD 0.03
(-3.03%)
HKD 0.03
(-3.03%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | - HKD | -249.11% |
| 2022 | -47.06 Million HKD | -10.59% |
| 2021 | -42.55 Million HKD | -205.37% |
| 2020 | 40.38 Million HKD | -86.79% |
| 2019 | 305.8 Million HKD | 52.67% |
| 2018 | 200.3 Million HKD | 233.92% |
| 2017 | 59.98 Million HKD | 853.21% |
| 2016 | -7.96 Million HKD | 29.67% |
| 2015 | -11.32 Million HKD | -119.57% |
| 2014 | 57.85 Million HKD | 8.22% |
| 2013 | 53.46 Million HKD | -28.47% |
| 2012 | 74.74 Million HKD | -39.09% |
| 2011 | 122.69 Million HKD | -76.42% |
| 2010 | 520.37 Million HKD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 9.56 Million HKD | 0.0% |
| 2023 Q1 | -18.93 Million HKD | 71.04% |
| 2023 Q2 | -74.23 Million HKD | -292.0% |
| 2023 FY | -164.3 Million HKD | -249.11% |
| 2023 Q4 | -90.06 Million HKD | -230.82% |
| 2023 Q3 | -27.22 Million HKD | 63.33% |
| 2022 Q1 | -19.57 Million HKD | 0.7% |
| 2022 FY | -47.06 Million HKD | -10.59% |
| 2022 Q4 | -65.39 Million HKD | -33.25% |
| 2022 Q3 | -49.07 Million HKD | 31.75% |
| 2022 Q2 | -71.89 Million HKD | -267.36% |
| 2021 FY | -42.55 Million HKD | -205.37% |
| 2021 Q1 | -26.34 Million HKD | 66.01% |
| 2021 Q2 | -58.33 Million HKD | -121.42% |
| 2021 Q3 | -2.76 Million HKD | 95.25% |
| 2021 Q4 | -19.71 Million HKD | -612.07% |
| 2020 FY | 40.38 Million HKD | -86.79% |
| 2020 Q1 | 6.54 Million HKD | 104.77% |
| 2020 Q2 | 91.83 Million HKD | 1303.48% |
| 2020 Q4 | -77.5 Million HKD | 0.0% |
| 2019 Q2 | 116.34 Million HKD | 107.41% |
| 2019 Q3 | 57.45 Million HKD | -50.62% |
| 2019 Q1 | 56.09 Million HKD | 151.24% |
| 2019 FY | 305.8 Million HKD | 52.67% |
| 2019 Q4 | -137.3 Million HKD | -338.98% |
| 2018 Q2 | 43.54 Million HKD | 0.0% |
| 2018 Q4 | 22.32 Million HKD | 0.0% |
| 2018 FY | 200.3 Million HKD | 233.92% |
| 2018 Q1 | 43.54 Million HKD | 583.89% |
| 2018 Q3 | 22.32 Million HKD | -48.72% |
| 2017 Q1 | 11.84 Million HKD | 295.34% |
| 2017 FY | 59.98 Million HKD | 853.21% |
| 2017 Q4 | 6.36 Million HKD | 0.0% |
| 2017 Q3 | 6.36 Million HKD | -46.25% |
| 2017 Q2 | 11.84 Million HKD | 0.0% |
| 2016 Q2 | -12.33 Million HKD | 0.0% |
| 2016 Q4 | -6.06 Million HKD | 0.0% |
| 2016 Q3 | -6.06 Million HKD | 50.85% |
| 2016 Q1 | -12.33 Million HKD | 9.87% |
| 2016 FY | -7.96 Million HKD | 29.67% |
| 2015 Q2 | -6.61 Million HKD | 0.0% |
| 2015 Q3 | -13.68 Million HKD | -107.07% |
| 2015 Q4 | -13.68 Million HKD | 0.0% |
| 2015 FY | -11.32 Million HKD | -119.57% |
| 2015 Q1 | -6.61 Million HKD | -187.54% |
| 2014 Q3 | -2.29 Million HKD | -123.48% |
| 2014 Q4 | -2.29 Million HKD | 0.0% |
| 2014 Q2 | 9.78 Million HKD | 0.0% |
| 2014 Q1 | 9.78 Million HKD | -7.89% |
| 2014 FY | 57.85 Million HKD | 8.22% |
| 2013 Q3 | 10.62 Million HKD | 664.57% |
| 2013 FY | 53.46 Million HKD | -28.47% |
| 2013 Q1 | 1.39 Million HKD | 113.74% |
| 2013 Q2 | 1.39 Million HKD | 0.0% |
| 2013 Q4 | 10.62 Million HKD | 0.0% |
| 2012 FY | 74.74 Million HKD | -39.09% |
| 2012 Q3 | -10.11 Million HKD | -199.99% |
| 2012 Q2 | 10.11 Million HKD | 0.0% |
| 2012 Q4 | -10.11 Million HKD | 0.0% |
| 2012 Q1 | 10.11 Million HKD | 0.0% |
| 2011 Q2 | 27.59 Million HKD | 0.0% |
| 2011 Q4 | 10.11 Million HKD | -63.32% |
| 2011 FY | 122.69 Million HKD | -76.42% |
| 2011 Q1 | 27.59 Million HKD | 0.0% |
| 2011 Q3 | 27.59 Million HKD | 0.0% |
| 2010 Q4 | 27.59 Million HKD | -64.87% |
| 2010 Q1 | 78.54 Million HKD | 0.0% |
| 2010 Q2 | 78.54 Million HKD | 0.0% |
| 2010 FY | 520.37 Million HKD | 0.0% |
| 2010 Q3 | 78.54 Million HKD | 0.0% |
| 2009 Q4 | 78.54 Million HKD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | 100.0% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 100.0% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 100.0% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | 100.0% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 100.0% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | 100.0% |
| Essex Bio-Technology Limited | 310.32 Million HKD | 100.0% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 100.0% |
| SSY Group Limited | 1.63 Billion HKD | 100.0% |
| JBM (Healthcare) Limited | 174.2 Million HKD | 100.0% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | 100.0% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 100.0% |